Actualités Theratechnologies Inc - TH | Actions Toronto Stock Exchange

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22...

Theratechnologies Appoints Jordan Zwick to its Board of Directors

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose...

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

MONTREAL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million...

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as...

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Votre Hub pour des idées et discussions en direct en temps réel

TH Actualités

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Actualités

Theratechnologies Inc (TH)

Votre Hub pour des idées et discussions en direct en temps réel

TH Actualités

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Theratechnologies Appoints Jordan Zwick to its Board of Directors

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités